ASCO 2018 ASCO18 pembrolizumab nivolumab durvalumab atezolizumab avelumab ipilimumab tremelimumab olaparib rucaparib niraparib PARP palbociclib ribociclib abemaciclib CDK46 osimertinib cabozantinib lenvatinib lorlatinib

Updates from the ASCO 2018 Annual Meeting (#asco18)

The ASCO 2018 Annual Meeting was held from June 1 to 5 in Chicago. MediPaper has summarised the key papers from the ASCO 2018, including the KEYNOTE-224, CELESTIAL, and REACH-2 studies in hepatocellular carcinoma.

Other specific interest goes to the ASCO 2018 non-small cell lung cancer this year as well as the breast cancer track.

SaveSave

ASCO 2018 NSCLC: The ASCO18 Lung Cancer Track Summarised

Non-small cell lung cancer (NSCLC): a key feature of the American Society of Clinical Oncology (ASCO) 2018 annual meeting. This year, encouraging results with single-agent immunotherapy (I-O) and combinations of I-O with chemotherapy (CTx), including the CheckMate 227 with nivolumab (NIVO), IMpower131 and IMpower150 studies with atezolizumab (ATEZO), and KEYNOTE-042 and KEYNOTE-407 studies with pembrolizumab (PEMBRO). Furthermore, important Asian data on treatments for epidermal growth-factor recptor (EGFR) mutation-positive (mu+) NSCLC (ARCHER 1050, NEJ009, NEJ026, and JO25567).

ASCO 2018 Breast Cancer: The ASCO18 breast cancer track summarised

Breast cancer: a front-runner when it comes to the development of novel therapeutic strategies. With the advent of newer targeted- and immunotherapies, oncologists have an increment of options to offer their patients. The American Society of Clinical Oncology’s (ASCO) 2018 Breast Cancer track offered an extensive look at the latest advancements and updates from on-going trials covering the various subtypes of breast cancer.

ASCO 2018 HCC: The ASCO18 hepatocellular cancer track summarised

This year’s American Society of Clinical Oncology (ASCO) annual meeting includes two Phase III studies in the second-line treatment of the disease. Moreover, data with several immune-checkpoint inhibitors were presented, including the KEYNOTE-224 with pembrolizumab. Welcome to the summary of the ASCO 2018 HCC track.